A fourth dose of bivalent or monovalent BA.1-adapted BNT162b2 vaccines was safe and elicited robust neutralizing responses in adults aged 18 to 55 years.

COVID-19 vaccine recommendations could be changing, according to the U.S. Food and Drug Administration. FDA leaders said on May 20 that clinical trials will be required to approve annual COVID-19 ...

Moderna shares tumbled last week after the Food and Drug Administration refused to review an application for its new seasonal flu vaccine. Now the FDA seems to have changed its tune.

Kendra Pierre-Louis: For Scientific American’s Science Quickly, I’m Kendra Pierre-Louis, in for Rachel Feltman. You’re listening to our weekly science news roundup. Let’s start off with a vaccine 180.

Feb 19 (Reuters) - German biopharmaceutical company BioNTech (22UAy.DE), opens new tab sued Moderna (MRNA.O), opens new tab in Delaware federal court on Thursday, alleging that Moderna's COVID-19 shot ...

Politico has reported that the White House isn’t happy with the FDA’s recent actions surrounding vaccines, fueling public scrutiny of internal decision-making at the regulator. The FDA’s quick ...

Moderna Inc.'s mNexspike Covid-19 vaccine infringes BioNTech SE’s patent on an mRNA design that uses only key portions of the coronavirus spike protein rather than the full-length version, a federal ...